A proteomic approach to the identification of lung cancer markers

Disease Markers

Volumn 17, Issue 4, 2001, Pages 295-300

  Hanash, S ^a   Brichory, F ^a   Beer, D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cancer; Lung; Markers; Proteomics

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; PROTEIN; PROTEOME; RNA; TUMOR ANTIGEN;

BLOOD ANALYSIS; CANCER; CELL LINE; DISEASE MARKER; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; LUNG CARCINOMA; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SEROLOGY; TISSUE; TUMOR; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 0035666838     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/657605     Document Type: Review

References (47)

1. Identification of gel-separated tumor marker proteins by mass spectrometry
2. Detection of polypeptides associated with the histopathological differentiation of primary lung carcinoma
3. Lung tumor cells: A multivariate approach to cell classification using two-dimensional protein pattern
4. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients
5. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
6. Human lung cancer antigens recognized by autologous antibodies: Definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3
7. p53 Antibodies in the sera of patients with various types of cancer: A review
8. Infrequent presence of anti-c-Myc antibodies and absence of c-Myce oncoprotein in sera from lung cancer patients
9. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma
10. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer
11. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer
12. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies
13. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain
14. Serum levels of interleukin 6 in patients with lung cancer
15. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer
16. Two-dimensional polyacrylamide gel electrophoresis of proteins
17. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity
18. Diagnostic immunocytochemistry: Achievements and challenges
19. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients
20. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients
21. The humoral response to the tumor-suppressor gene product p53 in human cancer: Implications for diagnosis and therapy
22. New paths in human cancer serology
23. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma
24. Proteomics-based identification of PGP 9.5 as a tumor antigen that induces a humoral immune response in lung cancer
25. Molecular cloning of cDNA coding for human PGP 9.5 protein. A novel cytoplasmic marker for neurones and neuroendocrine cells
26. The ubiquitin system
27. The ubiquitin-proteasome pathway in cancer
28. Ubiquitin-dependent protein degradation
29. Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung
30. Serial analysis of gene expression in non-small cell lung cancer
31. Chromogranin A gene expression in non-small cell lung carcinomas
32. Neural markers in carcinoma of the lung
33. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer
34. Human procathepsin B interacts with annexin II tetramer on the surface of tumor cells
35. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity
36. Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis
37. Glycosylation of annexin I and annexin II
38. Annexins and protein kinases C
39. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity
40. Primary structure of bovine calpactin I heavy chain (p36), a major cellular substrate for retroviral protein-tyrosine kinases: Homology with the human phospholipase A2 inhibitor lipocortin
41. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer
42. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer
43. IL-6 stimulates annexin 1 expression and translocation and suggests a new biological role as class II acute phase protein
44. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
45. Cellular responses to interferon-gamma
46. Lipocortin-1 immunoreactivity in central and peripheral nervous system glial tumors